Chudleigh Richard A, Platts Julia, Bain Stephen C
Singleton Hospital, Swansea Bay University Health Board, Swansea, UK.
Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK.
Diabetes Metab Syndr Obes. 2020 Feb 18;13:433-438. doi: 10.2147/DMSO.S193693. eCollection 2020.
Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW "long-acting" GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.
自2006年每日两次注射的艾塞那肽获批以来，胰高血糖素样肽-1（GLP-1）受体激动剂一直作为2型糖尿病患者的降糖疗法。从那时起，肽化学和给药方式的进步使得此类肽能够每日一次给药，最近还能每周一次给药，目前临床实践中有三种每周一次的“长效”GLP-1受体激动剂。这篇简短的综述描述了现代2型糖尿病降糖疗法的治疗格局，特别关注长效GLP-1受体激动剂。讨论了现有每周一次的GLP-1受体激动剂的疗效和副作用情况，重点是头对头临床试验比较。还对心血管结局试验进行了评估，对每种每周一次的GLP-1受体激动剂都进行了评估，得出了关于它们相对有效性的临床结论。
